Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 6:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 1,668 matching trials from the live ClinicalTrials.gov search.
Conditions
HIV Infection
Interventions
DOR/ISL, BIC/FTC/TAF, Placebo to BIC/FTC/TAF, Placebo to FDC DOR/ISL
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
28
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 24 more
Completed Phase 4 Interventional Results available

Novel Combination Therapy for Osteoporosis in Men

NCT03994172
Conditions
Male Osteoporosis
Interventions
Teriparatide or human parathyroid hormone (PTH) 1-34, Cinacalcet, placebo tablet, Calcium citrate tablet, Vitamin D3
Drug · Dietary Supplement
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years to 85 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
San Francisco, California
Conditions
Metastatic Breast Cancer
Interventions
Inavolisib, Phesgo, Placebo, Taxane-based Chemotherapy, Optional Endocrine Therapy of Investigator's Choice
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
20
States / cities
Gilbert, Arizona • Burbank, California • Corona, California + 17 more
Conditions
NASH
Interventions
K-877-ER, CSG452, Placebo
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
37
States / cities
Tucson, Arizona • Little Rock, Arkansas • Lincoln, California + 30 more
Conditions
Nonalcoholic Steatohepatitis
Interventions
Obeticholic Acid, Atorvastatin, Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
22
States / cities
Phoenix, Arizona • La Jolla, California • Rialto, California + 19 more
Conditions
Tinnitus
Interventions
incobotulinum toxin A, Placebo-Saline
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Peripheral Vascular Disease, Intermittent Claudication, Peripheral Arterial Disease
Interventions
Levocarnitine tartrate, cilostazol
Dietary Supplement · Drug
Lead sponsor
Colorado Prevention Center
Other
Eligibility
40 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
24
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 18 more
Conditions
Rosacea
Interventions
Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel, Placebo gel
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Stanford, California • Boston, Massachusetts
Conditions
Urinary Incontinence
Interventions
solifenacin succinate, tamsulosin, placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
45 Years and older · Male only
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
74
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tuscon, Arizona + 67 more
Conditions
Plaque Psoriasis
Interventions
Acitretin (also called U0279), Placebo, Etanercept
Drug · Biological
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
San Francisco, California • Louisville, Kentucky • New York, New York
Conditions
Pneumonia, Bacterial, Community-Acquired Infections, Nosocomial Infection, Pneumonia, Ventilator-Associated
Interventions
Cefepime placebo, Cefepime, Doripenem, Doripenem placebo, Amoxicillin/clavulanate potassium
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
3 Months to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Little Rock, Arkansas • Cleveland, Ohio • Toledo, Ohio + 1 more
Conditions
Inflammatory Bowel Diseases, Clostridium Difficile Infection
Interventions
Bezlotoxumab, Placebo, Fecal Microbiota Transplantation
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Systemic Sclerosis
Interventions
Belimumab, Mycophenolate Mofetil, Placebo Infusion
Drug · Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Conditions
Asthma
Interventions
FP, SFC, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Osteoarthritis of the Knee
Interventions
ABT-652 NSAID, Placebo NSAID
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
40 Years to 75 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
31
States / cities
Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 27 more
Conditions
HIV Infections
Interventions
Capravirine, Nelfinavir mesylate
Drug
Lead sponsor
Agouron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
San Diego, California
Conditions
Convergence Insufficiency, Binocular Vision Disorder
Interventions
Home-based Pencil Push-Up Therapy, Home-based Pencil Push-ups with Computer Vision Therapy/Orthoptics, Office-based Vision Therapy/Orthoptics, Placebo Office-based Vision Therapy/Orthoptics
Behavioral
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
9 Years to 18 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
9
States / cities
Birmingham, Alabama • Fullerton, California • La Jolla, California + 6 more
Conditions
Hypercholesterolemia
Interventions
Lapaquistat acetate and stable statin therapy, Stable statin therapy
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
649 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
13
States / cities
Santa Ana, California • Chicago, Illinois • Iowa City, Iowa + 10 more
Conditions
Multiple Myeloma
Interventions
A (Thalidomide + Dexamethasone), B (Placebo + Dexamethasone)
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
26
States / cities
Hoover, Alabama • Tucson, Arizona • Los Angeles, California + 20 more
Active, not recruiting Phase 3 Interventional

Phase III Study of AK112 for NSCLC Patients

NCT06396065
Conditions
Non-Squamous Non-small Cell Lung Cancer
Interventions
AK112 Injection, Placebo Injection
Drug
Lead sponsor
Summit Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
43
States / cities
Bakersfield, California • La Jolla, California • Los Angeles, California + 35 more
Completed Phase 4 Interventional Results available

Niacin, N-3 Fatty Acids and Insulin Resistance

NCT00286234
Conditions
Metabolic Syndrome, Hypertriglyceridemia
Interventions
omega-3 acid ethyl esters, extended release niacin, placebo, combined treatment
Drug
Lead sponsor
University of South Dakota
Other
Eligibility
40 Years to 69 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Conditions
HIV Coinfection
Interventions
Maraviroc, Placebo
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
24
States / cities
Bakersfield, California • Los Angeles, California • Oakland, California + 16 more
Conditions
Non-small Cell Lung Cancer
Interventions
Tomivosertib, Pembrolizumab, Pemetrexed
Drug · Biological
Lead sponsor
Effector Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
131
States / cities
Daphne, Alabama • Mobile, Alabama • Glendale, Arizona + 105 more
Conditions
Loss-of-Control Eating, Obesity/Overweight
Interventions
Naltrexone and Bupropion (NB) medication, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut